NKGen Biotech Inc (NKGN) Stock: Evaluating the Market Performance

Moreover, the 36-month beta value for NKGN is 0.54.

The public float for NKGN is 8.65M and currently, short sellers hold a 9.76% of that float. On April 04, 2024, NKGN’s average trading volume was 2.83M shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

NKGN) stock’s latest price update

NKGen Biotech Inc (NASDAQ: NKGN)’s stock price has dropped by -14.84 in relation to previous closing price of 1.82. Nevertheless, the company has seen a loss of -19.27% in its stock price over the last five trading days. InvestorPlace reported 2024-03-06 that NKGen Biotech (NASDAQ: NKGN ) stock is soaring higher on Wednesday alongside heavy pre-market trading of the clinical-stage biotechnology company’s shares. This has more than 6 million shares of NKGN stock changing hands as of this writing.

NKGN’s Market Performance

NKGen Biotech Inc (NKGN) has seen a -19.27% fall in stock performance for the week, with a 85.61% gain in the past month and a -48.84% plunge in the past quarter. The volatility ratio for the week is 9.84%, and the volatility levels for the past 30 days are at 34.02% for NKGN. The simple moving average for the past 20 days is -21.00% for NKGN’s stock, with a -71.26% simple moving average for the past 200 days.

NKGN Trading at -9.00% from the 50-Day Moving Average

After a stumble in the market that brought NKGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.97% of loss for the given period.

Volatility was left at 34.02%, however, over the last 30 days, the volatility rate increased by 9.84%, as shares surge +79.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.38% lower at present.

During the last 5 trading sessions, NKGN fell by -19.27%, which changed the moving average for the period of 200-days by -84.92% in comparison to the 20-day moving average, which settled at $1.9965. In addition, NKGen Biotech Inc saw -43.64% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at NKGN starting from Song Paul Y., who purchase 76 shares at the price of $3.29 back on Dec 07 ’23. After this action, Song Paul Y. now owns 171,121 shares of NKGen Biotech Inc, valued at $250 using the latest closing price.

Song Paul Y., the Chief Executive Officer of NKGen Biotech Inc, purchase 75 shares at $3.32 during a trade that took place back on Dec 06 ’23, which means that Song Paul Y. is holding 171,045 shares at $250 based on the most recent closing price.

Stock Fundamentals for NKGN

Equity return is now at value -46.90, with -32.46 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 0.27.

Conclusion

To wrap up, the performance of NKGen Biotech Inc (NKGN) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts